Retatrutide expanded access: how Lilly's program actually works

On August 3, 2026, STAT reported that Eli Lilly had opened an expanded access program for retatrutide — the first legitimate route to the drug outside a clinical trial. ^[1] This page explains what that means in practice, because "expanded access" is one of the most misunderstood phrases in medicine, and the misunderstanding is being actively exploited by sellers of fake "early access" products.

What expanded access is

Expanded access (sometimes called "compassionate use") is an FDA-recognized pathway that lets a company provide an investigational drug to specific patients outside its trials. It is not a product launch, not a waitlist you join, and not something you can buy. Three features define Lilly's program as reported: ^[1]

1. It's for patients who meet medical criteria set by the program.
2. It's for people who can't join a clinical trial — trials remain the primary route, and the program doesn't replace them.
3. The treating physician must apply. Patients cannot apply directly; the request goes from your doctor to Lilly.

That third point is the one to internalize. If you want to pursue expanded access, the entire path runs through a licensed clinician who treats you, examines you, and takes responsibility for the request.

Who might qualify

As reported by outlets citing a Lilly spokesperson, the program requires all of the following at once: ^[5]

1. Age 18 or older.
2. Refractory obesity despite tolerating the highest approved dose of an obesity therapy — meaning approved medications were genuinely tried at full dose, not skipped.
3. At least two serious or life-threatening obesity-related complications for which the patient is already receiving care.
4. Unable to enroll in an ongoing retatrutide trial — screened out, excluded, or no reachable site — having discussed all standard treatment options with a doctor.

That is a deliberately narrow gate: most people interested in retatrutide won't meet it, and whether your situation fits is exactly the conversation to have with your physician.

What we can say with confidence is who the program is not for: it is not a general-availability shortcut for people who simply don't want to wait for approval. Retatrutide remains investigational, with a U.S. FDA submission planned for Q1 2027 ^[3] — the program narrows the gap for specific medical situations, nothing more.

How to raise it with your doctor

A productive version of that appointment looks like this:

• Start with the trial question. Since the program is for people who can't join a trial, check the trial landscape first — your doctor will likely ask.
• Ask directly: "Would you consider submitting an expanded access request to Lilly for retatrutide on my behalf, and do you think I'd meet medical criteria?"
• Expect a real evaluation. A physician who says yes is taking on regulatory paperwork and clinical responsibility. A physician who says no, or who recommends an approved medication instead, is doing their job — approved GLP-1 drugs exist today and may be the better answer for you. Our should-I-wait article covers that decision.
• No promises. Requests are evaluated case by case. Nobody — not your doctor, not this site — can guarantee an outcome.

If your current provider isn't familiar with obesity medicine, find a weight-loss provider near you — our guide to choosing one covers the credentials to look for.

What expanded access is not

Because retatrutide remains unapproved and unavailable for sale ^[2], sellers have built a market around words like "early access." None of it is this program:

• "Early access retatrutide" websites — the FDA states retatrutide cannot be used in compounding under federal law, and has issued warning letters to sellers marketing it as a research product. ^[4]
• Clinics offering it "off-menu" — no clinic can lawfully stock or prescribe retatrutide today. Expanded access supplies a named patient via an approved physician request; it does not supply clinics.
• Paid waitlists or "reservations" — there is no price, no brand name, and no commercial supply to reserve. ^[2]

The full picture of that gray market is in our research-peptide warning.

The bottom line

Expanded access is real, narrow, and physician-driven. If you think you might qualify, the next step isn't a website — it's an appointment. Check clinical trials first, bring the question to a clinician you trust, and for everything that changes between now and FDA review, the approval tracker and our email updates will keep you current.